The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
1 Year | 5 Year | 5 Year Annualized | Since IPO | |
---|---|---|---|---|
CRVS | -7.35% | +81.31% | +12.64% | -49% |
S&P | +14.5% | +93.32% | +14.09% | +229% |
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.
Q2 2025 | YOY Change | |
---|---|---|
Revenue | $0.00M | 0.0% |
Gross Profit | -$0.03M | -38.1% |
Market Cap | $308.46M | 170.9% |
Market Cap / Employee | $9.95M | 0.0% |
Employees | 31 | 10.7% |
Net Income | -$8.00M | -87.7% |
EBITDA | -$10.23M | -73.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
Q2 2025 | YOY Change | |
---|---|---|
Net Cash | $14.69M | -1.0% |
Accounts Receivable | $0.09M | 145.7% |
Inventory | 0 | 0.0% |
Q2 2025 | YOY Change | |
---|---|---|
Long Term Debt | $0.73M | 0.0% |
Short Term Debt | $0.36M | -49.3% |
Q2 2025 | YOY Change | |
---|---|---|
Return On Assets | -58.61% | -21.7% |
Return On Invested Capital | -75.83% | -24.5% |
Q2 2025 | YOY Change | |
---|---|---|
Free Cash Flow | -$5.89M | -7.5% |
Operating Free Cash Flow | -$5.78M | -5.4% |
Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
---|---|---|---|---|---|
Price to Book | 6.45 | 26.98 | 6.63 | 5.53 | 106.65% |
Price to Tangible Book Value | 6.45 | 26.98 | 6.63 | 5.53 | 106.66% |
Enterprise Value to EBITDA | -42.97 | -38.94 | -19.79 | -23.24 | 121.23% |
Return on Equity | -200.5% | -174.9% | -100.1% | -68.7% | 52.89% |
Total Debt | $0.35M | $1.12M | $1.15M | $1.08M | 54.71% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.